{"id":"NCT01730534","sponsor":"AstraZeneca","briefTitle":"Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events","officialTitle":"Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-25","primaryCompletion":"2018-09-11","completion":"2018-09-11","firstPosted":"2012-11-21","resultsPosted":"2019-12-26","lastUpdate":"2019-12-26"},"enrollment":17190,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","High Risk for Cardiovascular Event"],"interventions":[{"type":"DRUG","name":"Dapagliflozin 10 mg","otherNames":[]},{"type":"DRUG","name":"Placebo tablet","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.","primaryOutcome":{"measure":"Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke","timeFrame":"up to 5.2 years","effectByArm":[{"arm":"Dapa 10 mg","deltaMin":756,"sd":null},{"arm":"Placebo","deltaMin":803,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.172"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":805,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Philippines","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["38770818","36878239","36857035","35997319","35857296","35510542","35015847","34427295","34233928","34129237","33851953","33653824","33611623","32795086","31983236","31843945","31474116","31196815","30882239","30882238","30415602","29898853","29693360","27408945","27009868"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D1693C00001&attachmentIdentifier=9c285ea0-c985-475c-9454-693ef18bed8c&fileName=DECLARE_TIMI_58_D1693C00001-revised-csp_5_Redacted_version.pdf&versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D1693C00001&attachmentIdentifier=0d14dc43-84c6-4ae3-a27d-b04c4a7b32a7&fileName=DECLARE_TIMI_58_Trial_D1693C00001_Statistical_Analysis_Plan_Redacted_version.pdf&versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":3205,"n":8574},"commonTop":["Renal impairment","Acute kidney injury","Chronic kidney disease"]}}